FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

A new government program will give pregnant mothers and newborns free access to RSV vaccines, a move that is expected to ...

At the ITF Masters event in Bedford, NS, last month, the Canadians cleaned up by winning almost every title at the Atlantic Masters.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...